Zhongtai: High-performance carbon fiber for commercial space industry ushers in new era of rising prices and demand, suggest focusing on industry leaders.
Carbon fiber and composite materials will greatly benefit from the expansion of the commercial aerospace market space and the promotion of localization.
Zhongtai released a research report stating that the commercial space industry is currently at a critical stage of transitioning from technology validation to large-scale deployment. Carbon fiber and composite materials, as key materials for achieving lightweighting and performance enhancement, will deeply benefit from the expansion of the commercial space market and the promotion of localization. The company recommends focusing on leading high-performance carbon fiber companies such as Weihai Guangwei Composites (300699.SZ), Zhongfu Shenying Carbon Fiber (688295.SH), Sinofibers Technology (300777.SZ), Jilin Chemical Fibre Stock (000420.SZ), and JILIN TANGU.
Key points from Zhongtai:
- Lightweighting is crucial for cost competitiveness in the commercial space industry, making carbon fiber composites a strategic necessity.
- Demand for carbon fiber in the commercial space market is expected to reach 6.7 billion RMB by 2030, with satellite demand leading the way.
- The use of carbon fiber in space applications, such as satellites and rockets, is increasing due to its superior performance characteristics.
The report also discusses the potential supply constraints, technological advancements, and the market outlook for carbon fiber in the commercial space industry. It highlights the importance of lightweight materials in reducing costs and improving efficiency in the space industry. Additionally, it points out the potential risks, such as unexpected policy changes or delays in rocket launches, that could affect the market.
Related Articles

Haisco Pharmaceutical Group (002653.SZ): HSK50042 tablet obtains clinical trial approval for new indications.

Ningbo Sanxing Medical Electric's subsidiary signs a 9.49 billion yuan overseas operating contract.

Zhejiang Medicine (600216.SH): ARX305 initiates Phase II clinical trial.
Haisco Pharmaceutical Group (002653.SZ): HSK50042 tablet obtains clinical trial approval for new indications.

Ningbo Sanxing Medical Electric's subsidiary signs a 9.49 billion yuan overseas operating contract.

Zhejiang Medicine (600216.SH): ARX305 initiates Phase II clinical trial.

RECOMMEND





